Details of the Drug

General Information of Drug (ID: DMKBYWI)

• Drug Name: Trifluoperazine
• Synonyms: Calmazine; Eskazine; Fluoperazine; Flurazine; Modalina; Stelazine; Stellazine; TFP; Trifluoperazin; Trifluoperazina; Trifluoperazinum; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; PMS Trifluoperazine; Stelazine Concentrate; Trifluoperazina [Italian]; Trifluoperazine HCl; Trifluoperazine dihydrochloride; Trifluoroperazine dihydrochloride; Tripfluoperazine Hydrochloride; NCI17474; RP 7623; SKF 5019; Apo-Trifluoperazine; Eskazine (TN); Eskazinyl (TN); Jatroneural (TN); Modalina (TN); Novo-Trifluzine; Stelazine (TN); Terfluzine (TN); Trifluoperaz (TN); Trifluoperazina [INN-Spanish]; Trifluoperazine (INN); Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine

Indication

Disease Entry	ICD 11	Status	REF
Anxiety	N.A.	Approved	[1]
Schizophrenia	6A20	Approved	[2]

• Therapeutic Class: Antipsychotic Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  N05AB06: Trifluoperazine
  N05AB: Phenothiazines with piperazine structure
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
  N05AB06: Trifluoperazine
  N05AB: Phenothiazines with piperazine structure
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
  N05AB06: Trifluoperazine
  N05AB: Phenothiazines with piperazine structure
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 407.5
  Logarithm of the Partition Coefficient (xlogp); 5
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 7
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 10 - 20 hours [4]
  Metabolism: The drug is metabolized via the hepatic []
  Water Solubility: The ability of drug to dissolve in water is measured as 50 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Tardive dyskinesia	Not Available	DRD3	OT0OFFKB	[5]
Tardive dyskinesia	Not Available	DRD4	OTAJTO7N	[5]
Tardive dyskinesia	Not Available	DRD2	OTBLXKEG	[5]

• Chemical Identifiers:
  Formula: C21H24F3N3S
  IUPAC Name: 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine
  Canonical SMILES: CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
  InChI: InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
  InChIKey: ZEWQUBUPAILYHI-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5566
  ChEBI ID: CHEBI:45951
  CAS Number: 117-89-5
  UNII: 214IZI85K3
  DrugBank ID: DB00831
  TTD ID: D0R4OM
  VARIDT ID: DR00664
  INTEDE ID: DR1641
  ACDINA ID: D00703
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calmodulin (CALM)	TTV3NH6	CALM1_HUMAN ; CALM2_HUMAN ; CALM3_HUMAN	Inhibitor	[6]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[8]
Dimethylaniline oxidase 2 (FMO2)	DEIASEZ	FMO2_HUMAN	Substrate	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[10]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[10]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[11]
D(2) dopamine receptor (DRD2)	OTBLXKEG	DRD2_HUMAN	Drug Response	[5]
D(3) dopamine receptor (DRD3)	OT0OFFKB	DRD3_HUMAN	Drug Response	[5]
D(4) dopamine receptor (DRD4)	OTAJTO7N	DRD4_HUMAN	Drug Response	[5]
E3 ubiquitin-protein ligase parkin (PRKN)	OTJBN41W	PRKN_HUMAN	Protein Interaction/Cellular Processes	[12]
Flavin-containing monooxygenase 2 (FMO2)	OTUJUL9S	FMO2_HUMAN	Biotransformations	[9]
Hypoxia-inducible factor 1-alpha (HIF1A)	OTADSC03	HIF1A_HUMAN	Gene/Protein Processing	[13]
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Gene/Protein Processing	[14]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 06 Mental, behavioural or neurodevelopmental disorder
• Disease Class: ICD-11: 6A20 Schizophrenia
• The Studied Tissue: Pre-frontal cortex
• The Studied Disease: Schizophrenia [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Calmodulin (CALM)	DTT	CALM	6.44E-01	0.09	0.15
Calmodulin (CALM)	DTT	CALM	5.89E-01	-3.28E-04	-1.09E-03
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.19E-01	-1.32E-01	-2.77E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.65E-01	-1.47E-01	-4.48E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.73E-02	6.49E-02	3.07E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.45E-01	2.07E-02	1.74E-01

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 133 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	3.9692	6.4972	3.3022	9.7025
MEC1	CTRP2	4.4145	5.0559	4.3539	4.4088
JM1	CTRP2	4.1933	4.9297	4.1442	5.8396
MJ	CTRP2	1.5049	15.5563	-3.3901	36.377
SU-DHL-6	CTRP2	1.5287	4.0778	1.4217	23.7862
NALM-6	CTRP2	2.503	4.4011	2.4164	17.2269
OCI-AML-3	CTRP1	2.7339	4.2828	2.6836	33.5665
Ku812	CTRP2	2.8703	4.3059	2.825	14.6376
Peer	CTRP2	2.8897	4.4087	2.831	14.5543
MOTN-1	CTRP2	3.0055	5.4535	2.6955	14.6875
NCO2	CTRP2	3.0203	5.1049	2.8186	14.1923
Ri-1	CTRP2	3.0519	5.9418	2.5726	15.0153
KMS-21-BM	CTRP2	3.1415	4.4421	3.0958	12.8327
CML-T1	CTRP2	3.1571	4.4854	3.106	12.7473
RPMI-8402	CTRP2	3.1606	5.0129	2.9971	13.1214
KHM-1B	CTRP2	3.2188	4.553	3.1615	12.3578
PL21	CTRP2; CTRP1	3.2249	4.462	3.1832	12.3479
LP-1	CTRP2	3.2737	14.9648	-1.4591	28.1294
KE-37	CTRP2	3.3071	4.4963	3.2651	11.7167
SU-DHL-1	CTRP2	3.4053	4.5771	3.3581	11.0806
JURL-MK1	CTRP2	3.4058	5.0313	3.2597	11.427
JVM-3	CTRP2	3.4648	4.947	3.3462	10.9359
Daudi	CTRP2	3.4932	6.1968	2.9406	12.3798
SU-DHL-5	CTRP1	3.5035	4.0252	3.5028	22.2253
KMS-26	CTRP2	3.5173	4.382	3.5014	10.227
PF-382	CTRP2	3.5211	4.9291	3.412	10.527
Ki-JK	CTRP2	3.5231	4.6871	3.4663	10.3296
EM-2	CTRP2	3.6289	5.2695	3.4328	10.1261
M-07e	CTRP2	3.652	10.8237	0.9257	19.869
MOLM-13	CTRP2	3.6599	5.7236	3.3057	10.5141
P12-Ichikawa	CTRP2	3.7284	5.1563	3.5761	9.3043
THP-1	CTRP2; CTRP1	3.7423	4.8645	3.67	9.0118
AML-193	CTRP2	3.7465	5.109	3.6098	9.1273
WSU-DLCL2	CTRP2; CTRP1	3.771	4.5622	3.7514	8.6378
P31/FUJ	CTRP2	3.7729	5.7041	3.4339	9.7083
TALL-1 [Human adult T-ALL]	CTRP2	3.7984	6.3586	3.1894	10.5915
HT	CTRP2	3.7992	4.7103	3.7599	8.4296
RPMI-8226	CTRP2; CTRP1	3.8264	4.925	3.7479	8.4744
SUP-HD1	CTRP2	3.843	7.9492	2.5001	13.2563
NU-DUL-1	CTRP2; CTRP1	3.8574	19.6217	-3.2466	30.7729
KCL-22	CTRP2	3.8938	5.3804	3.6832	8.4211
GDM-1	CTRP2; CTRP1	3.8972	5.2476	3.735	8.3072
SUP-T11	CTRP2	3.9137	5.6029	3.623	8.592
NOMO-1	CTRP1	3.9488	5.2944	3.7757	17.1811
LAMA-84	CTRP2	3.9681	5.3466	3.7753	7.8617
DND-41	CTRP2	3.9829	5.6817	3.666	8.2347
KM-H2	CTRP2	3.9861	5.4509	3.7575	7.8769
L-428	CTRP2	3.9947	7.1794	3.0123	10.8091
DEL	CTRP2	3.9972	4.6847	3.9759	7.0486
ST486	CTRP2	4.008	5.2902	3.8379	7.5124
NCI-H929	CTRP2	4.0488	5.1553	3.9256	7.0683
EHEB	CTRP2	4.0538	6.0652	3.5801	8.3793
KE-97	CTRP2	4.0728	4.8386	4.0323	6.612
Jurkat	CTRP2	4.0916	5.2229	3.9509	6.8484
AMO1	CTRP2	4.0995	5.4993	3.8611	7.1628
MOLP-8	CTRP2	4.0997	6.9467	3.2246	9.6916
HuT 78	CTRP2	4.1041	6.4669	3.4518	8.7616
MV4-11	CTRP2	4.112	5.2041	3.9791	6.6841
KMS-20	CTRP2	4.1578	5.2406	4.017	6.4091
SKM-1	CTRP2; CTRP1	4.172	4.7556	4.1538	5.9645
KMS-11	CTRP2	4.1808	7.3275	3.1221	9.9169
KMS-28BM	CTRP2	4.2011	5.6322	3.9165	6.6688
HEL	CTRP2	4.2188	4.9903	4.1576	5.7127
KMS-34	CTRP2	4.2301	5.5219	3.9915	6.2999
MOLM-6	CTRP2	4.2374	6.2942	3.6643	7.5733
Karpas-422	CTRP2	4.2374	7.4493	3.1174	9.8045
KMS-12-BM	CTRP2	4.2509	6.2023	3.7198	7.3158
U-937	CTRP2; CTRP1	4.2542	4.9587	4.2059	5.5224
SUP-M2	CTRP2	4.2607	4.9346	4.2164	5.3739
KMS-27	CTRP2	4.2656	4.9314	4.2225	5.3372
Mono-Mac-6	CTRP2	4.2716	11.86	0.9729	18.2967
OCI-AML-2	CTRP2	4.2767	5.3306	4.1141	5.7017
Raji	CTRP2	4.2928	6.1005	3.8082	6.856
RS4;11	CTRP2	4.3011	6.2086	3.7672	6.9997
HDLM-2	CTRP2	4.3014	5.7047	3.9913	6.1069
Kasumi-2	CTRP2	4.3033	12.6505	0.6074	19.5471
RPMI-6666	CTRP2	4.3254	8.4668	2.7024	11.3195
MOLT-16	CTRP2	4.3407	5.6517	4.0548	5.7535
SU-DHL-4	CTRP2; CTRP1	4.3547	4.9796	4.3105	4.8397
Reh	CTRP2	4.3571	5.2102	4.2433	4.9858
SET-2	CTRP2	4.3647	5.0211	4.3088	4.7233
KMS-18	CTRP2	4.3701	9.1749	2.3934	12.4959
DB	CTRP2	4.3701	5.7223	4.055	5.6747
RL	CTRP2	4.3711	9.6309	2.1684	13.4145
SK-MM-2	CTRP2	4.3731	10.0817	1.9465	14.3085
OCI-Ly3	CTRP2	4.4066	5.243	4.2856	4.6841
JeKo-1	CTRP2	4.4173	10.1376	1.958	14.1677
JJN-3	CTRP2	4.4234	5.398	4.2456	4.7881
HPB-ALL	CTRP2	4.4344	5.0321	4.382	4.2465
EJM	CTRP2; CTRP1	4.4348	5.0358	4.3839	4.3309
MHH-CALL-4	CTRP2	4.4401	5.7256	4.1256	5.2129
L-540	CTRP2	4.4481	5.585	4.1948	4.9187
SUP-T1	CTRP2	4.4508	5.1939	4.3503	4.3142
TF-1	CTRP2	4.4541	4.9236	4.4287	4.0196
HD-MY-Z	CTRP2	4.456	8.5766	2.7668	10.7673
MM1.S	CTRP2	4.4632	5.466	4.2604	4.6222
REC-1	CTRP2	4.4678	5.7164	4.158	5.0123
Granta-519	CTRP2	4.4764	5.3738	4.3114	4.3886
RCH-ACV	CTRP2	4.4778	5.7332	4.1607	4.9756
ME1	CTRP2	4.4823	5.0662	4.4249	3.9462
Mono-Mac-1	CTRP2	4.4834	5.7065	4.1782	4.8917
SUP-B15	CTRP2	4.4926	5.1364	4.4148	3.9521
Karpas-299	CTRP2	4.5191	5.0809	4.4608	3.705
NB4	CTRP2	4.5263	4.9739	4.4965	3.5546
BV-173	CTRP2	4.5517	5.5306	4.3255	4.1305
U266B1	CTRP2	4.5548	10.3902	1.9532	13.8957
MOLM-16	CTRP2; CTRP1	4.5676	5.4888	4.3654	4.023
NU-DHL-1	CTRP2	4.5772	5.2134	4.4801	3.4629
OCI-M1	CTRP2	4.581	4.9874	4.5531	3.1835
MOLT-13	CTRP2	4.5865	5.2736	4.4677	3.4837
SU-DHL-8	CTRP2	4.5878	5.88	4.2041	4.5248
KYO-1	CTRP2	4.5899	5.4908	4.3821	3.8067
Ci-1	CTRP2	4.5992	4.9607	4.5785	3.0371
A3/Kawakami	CTRP2	4.6013	4.9635	4.5803	3.0243
SEM	CTRP2	4.6194	5.1183	4.5585	3.0478
HL-60	CTRP2	4.6213	5.5308	4.3969	3.6664
Kasumi-1	CTRP2	4.6321	16.563	-1.062	24.0948
SR	CTRP2	4.6512	5.2947	4.5281	3.0722
KMM-1	CTRP2	4.7006	6.7794	3.876	5.6174
L-363	CTRP2	4.7138	5.2303	4.6201	2.5454
OCI-Ly19	CTRP2	4.7156	5.9763	4.2824	3.8994
SU-DHL-10	CTRP2	4.7684	5.3146	4.6426	2.3103
Mino	CTRP2	4.7817	5.7166	4.4703	2.9729
Karpas-620	CTRP2	4.8262	5.6561	4.542	2.5745
SIG-M5	CTRP2	4.9327	5.7941	4.5729	2.2087
MC116	CTRP2	4.979	5.9906	4.5157	2.352
CMK	CTRP2	4.9931	5.7382	4.6538	1.7436
OCI-Ly10	CTRP2	5.0238	9.2835	2.9076	9.0159
MHH-CALL-3	CTRP2	5.0551	6.3067	4.4221	2.595
MOLP-2	CTRP2	5.0603	6.0749	4.5424	2.0797
OCI-AML-5	CTRP2	5.0703	13.6674	0.7544	17.4296
P3HR-1	CTRP2	5.1396	6.4416	4.4234	2.432
F-36P	CTRP2	5.9106	16.2517	0.1452	17.9242

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE15	CTRP2	4.4354	10.626	1.7311	15.036
TE8	CTRP2	4.4389	5.1955	4.3369	4.3987
TE-4	CTRP2	4.0937	5.6644	3.7902	7.4513
OE21	CTRP2	4.2819	5.1552	4.1795	5.4429
TE-10	CTRP2	4.2845	5.2149	4.163	5.4959
TE-9	CTRP2	4.2964	5.074	4.2198	5.2524
KYSE-140	CTRP2	4.3781	12.7959	0.6002	19.4108
KYSE-70	CTRP2	4.4171	5.4062	4.2357	4.8438
KYSE-510	CTRP2	4.435	10.8916	1.5987	15.5593
KYSE-180	CTRP2	4.4393	12.8	0.6515	19.0984
TE-14	CTRP2	4.4444	5.4615	4.2424	4.743
TE-11	CTRP2	4.457	12.4183	0.8571	18.3215
TE-5	CTRP2	4.4629	5.5558	4.2226	4.7703
KYSE-410	CTRP2	4.4793	5.9213	4.0772	5.3061
TE-6	CTRP2	4.4989	5.1667	4.4117	3.9452
KYSE-30	CTRP2	4.5054	4.9495	4.4791	3.6813
KYSE-520	CTRP2	4.5119	6.6159	3.7803	6.4393
TE-1	CTRP2	4.5458	5.1484	4.4687	3.5965
COLO 680N	CTRP2	4.5781	5.1626	4.4989	3.3899
OE33	CTRP2	4.5906	5.6176	4.327	4.0233
KYSE-150	CTRP2	5.0788	5.9649	4.6124	1.7504
KYSE-450	CTRP2	5.4826	6.9101	4.4466	1.7821
OE19	CTRP2	10.3692	26.3795	-1.5783	16.1904

Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	8.5506	18.1044	1.1544	10.286
DAN-G	CTRP2	3.3998	12.0813	0.0763	23.411
Panc 10.05	CTRP2	3.7313	6.3597	3.1198	12.7748
Panc 02.03	CTRP2	3.8296	5.2619	3.6535	8.7191
BxPC-3	CTRP2	3.9462	5.7614	3.5952	8.6088
HPAC	CTRP2	3.9842	5.0089	3.8969	7.3678
SNU-213	CTRP2	4.0827	4.9449	4.0203	6.6231
KP-3	CTRP2	4.1469	6.6969	3.388	8.9132
HuP-T4	CTRP2	4.2154	6.8638	3.3767	8.793
PaTu 8988t	CTRP2	4.3006	4.8533	4.2758	5.0399
Capan-2	CTRP2	4.3324	7.8623	3.0055	10.0496
TCC-Pan2	CTRP2	4.3717	5.0608	4.3057	4.7132
HuP-T3	CTRP2	4.3985	16.1707	-1.0658	24.5929
PaTu 8988s	CTRP2	4.4014	4.9499	4.3661	4.4056
PaTu 8902	CTRP2	4.4252	4.9626	4.3891	4.2499
Hs 766T	CTRP2	4.4357	20.3871	-3.1399	29.3613
PK-59	CTRP2	4.4583	5.3297	4.3093	4.4474
Panc 08.13	CTRP2	4.4661	5.1586	4.3788	4.1637
CFPAC-1	CTRP2	4.4793	5.5905	4.2247	4.7184
Panc 03.27	CTRP2	4.4798	8.9125	2.6218	11.3173
YAPC	CTRP2	4.4873	4.9252	4.4643	3.7903
MIA PaCa-2	CTRP2	4.4997	4.978	4.4667	3.7428
KP-4	CTRP2	4.5039	5.0276	4.4591	3.7572
L3.3	CTRP2	4.5302	4.9768	4.5001	3.5295
QGP-1	CTRP2	4.5382	5.1295	4.4666	3.6268
SU.86.86	CTRP2	4.5696	5.0765	4.5171	3.3482
Capan-1	CTRP2	4.5822	5.1655	4.5024	3.3646
KP-2	CTRP2	4.5827	4.9588	4.5611	3.1502
AsPC-1	CTRP2	4.5977	5.7209	4.2875	4.1635
SW1990	CTRP2	4.6222	5.3576	4.4719	3.3691
PSN1	CTRP2	4.6284	5.7784	4.2915	4.0711
Panc 05.04	CTRP2	4.643	6.6558	3.8838	5.7125
Panc 04.03	CTRP2	4.7275	5.275	4.6166	2.5214
HPAF-II	CTRP2	4.7561	6.8201	3.9062	5.3715
PK-45H	CTRP2	4.9543	5.8463	4.5661	2.1913
SUIT-2	CTRP2	4.9831	6.0464	4.4914	2.4454

Cancer Drug Sensitivity Data Curated from 47 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	1.3959	3.5823	1.271	19.6107
Mel Ho	CTRP2	2.6991	3.3626	2.6989	15.6254
MeWo	CTRP2	3.3199	5.7167	2.9439	12.8485
RPMI-7951	CTRP2	3.4456	4.6373	3.3915	10.8361
Hs 940.T	CTRP2	3.5365	6.4993	2.8582	14.5593
SK-MEL-1	CTRP2; CTRP1	3.5741	4.551	3.5437	9.9852
SK-MEL-5	CTRP2; CTRP1	3.5824	4.1174	3.5813	9.8305
G-361	CTRP2	3.6361	5.394	3.3996	10.2282
SK-MEL-24	CTRP2	3.6676	5.4819	3.4032	10.1235
A2058	CTRP2	3.7607	5.1067	3.6259	9.0259
IGR-1	CTRP2	3.8004	4.5692	3.781	8.3531
UACC-257	CTRP2	3.9583	4.6877	3.9341	7.3179
COLO 792	CTRP2	3.9768	4.858	3.9244	7.2928
SK-MEL-3	CTRP2	4.02	4.9695	3.946	7.0816
A-375	CTRP2; CTRP1	4.0685	4.8933	4.0184	6.764
A101D	CTRP2	4.141	4.9259	4.0882	6.2009
COLO 800	CTRP2	4.2137	5.2904	4.0604	6.0845
IGR-39	CTRP2	4.262	4.8393	4.2366	5.2992
HT-144	CTRP2	4.2801	4.9316	4.2382	5.2366
WM983B	CTRP2	4.2947	9.062	2.3811	12.7107
IGR-37	CTRP2	4.3581	4.9486	4.3192	4.7066
Hs 944.T	CTRP2	4.3597	8.8131	2.5629	11.8207
SK-MEL-2	CTRP2	4.3762	13.1941	0.4002	20.111
Hs 294T	CTRP2	4.3849	4.8285	4.37	4.4441
COLO 829	CTRP2	4.3914	8.5766	2.7084	11.1498
WM88	CTRP2	4.4181	4.9495	4.3842	4.2893
SK-MEL-28	CTRP2; CTRP1	4.4435	4.8551	4.4299	4.1419
WT2-iPS	CTRP2	4.4533	5.0355	4.4018	4.1179
SK-MEL-30	CTRP2	4.4665	4.9348	4.4399	3.9417
Mel JuSo	CTRP2	4.47	4.9821	4.4334	3.9533
Hs 852.T	CTRP2	4.5257	5.1229	4.4551	3.7062
WM793	CTRP2	4.5331	4.9893	4.5004	3.5193
Hs 895.T	CTRP2	4.5398	5.0473	4.4929	3.5257
K029AX	CTRP2	4.5438	4.9075	4.5285	3.3871
MDA-MB-435S	CTRP2	4.5553	4.9899	4.5244	3.3653
HMCB	CTRP2	4.5744	5.0891	4.5186	3.3278
IPC-298	CTRP2	4.5847	4.974	4.56	3.1479
WM266-4	CTRP2	4.5876	4.9063	4.5756	3.0841
LOX-IMVI	CTRP2	4.6009	5.0913	4.5468	3.1459
WM1799	CTRP2	4.6186	4.9663	4.5985	2.9058
Hs 936.T	CTRP2	4.6743	5.0247	4.6456	2.5655
UACC-62	CTRP2	4.7107	5.2068	4.6258	2.5324
SK-MEL-31	CTRP2	4.7323	5.3577	4.5867	2.6256
Hs 839.T	CTRP2	4.8684	15.3537	-0.2577	21.2392
CJM [Human melanoma]	CTRP2	5.014	5.7058	4.6881	1.5575
Hs 688(A).T	CTRP2	7.94	31.1956	-5.7034	27.9668
RVH-421	CTRP2	10.7489	26.5319	-1.3981	15.242

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MHH-NB-11	CTRP2	3.9145	5.2924	3.7356	8.1658
SK-N-SH	CTRP2	4.0183	7.5038	2.8816	11.285
SK-N-AS	CTRP2	4.354	5.1558	4.2579	4.9407
SK-N-BE(2)	CTRP2	4.3718	5.5485	4.1303	6.2186
KP-N-SI9s	CTRP2	4.418	5.0096	4.3699	4.3404
Kelly	CTRP2	4.4519	5.0813	4.3874	4.1741
NB1	CTRP2	4.5315	5.0021	4.4957	3.5413
CHP-126	CTRP2	7.1986	31.1808	-6.2748	29.8691

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-1079	CTRP2	2.851	4.438	2.7849	14.8379
HuCC-T1	CTRP2	4.1825	5.1686	4.0672	6.1508
SNU-478	CTRP2	4.2507	5.3924	4.0633	5.9679
HuH-28	CTRP2	4.3422	5.1163	4.2573	4.9782
SNU-869	CTRP2	4.5437	4.9918	4.5114	3.4478
SNU-1196	CTRP2	4.5587	5.0273	4.5189	3.3743
SNU-308	CTRP2	4.7221	5.5713	4.4804	3.0761

Cancer Drug Sensitivity Data Curated from 14 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MHH-ES-1	CTRP2	4.197	6.3113	3.616	7.8689
SK-N-MC	CTRP2	4.2697	4.8512	4.2428	5.2531
Hs 888.T	CTRP2	4.3649	5.3074	4.2174	5.0602
SW1353	CTRP2	4.3663	8.3866	2.7793	10.9112
Hs 822.T	CTRP2	4.3723	4.8731	4.3496	5.2696
SK-ES-1	CTRP2	4.4171	5.4156	4.2319	4.8585
MG-63	CTRP2	4.4889	4.9664	4.4576	3.8089
TC71	CTRP2	4.6021	4.9779	4.5781	3.0293
SJSA-1	CTRP2	4.623	5.2489	4.516	3.197
SaOS-2	CTRP2	4.691	5.8112	4.3376	3.7315
HOS	CTRP2	4.8527	10.9847	1.913	13.4451
CAL-78	CTRP2	4.9821	6.0839	4.4719	2.5295
G-292 clone A141B1	CTRP2	5.1084	8.1867	3.5262	6.2588
U2OS	CTRP2	8.999	24.2742	-1.5074	17.847

Cancer Drug Sensitivity Data Curated from 66 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HCC2218	CTRP2	0.3399	7.0207	-0.7384	34.5787
KPL-1	CTRP2	2.3271	3.1739	2.3264	19.3975
MCF-7	CTRP2; CTRP1	3.5347	5.4974	3.258	11.1364
HCC1395	CTRP2	3.6085	4.7262	3.5513	9.7622
HCC1954	CTRP2	3.7055	5.3461	3.491	9.6855
AU565	CTRP2	3.8364	5.7986	3.4641	10.8936
HCC1806	CTRP2	3.994	5.3383	3.8062	7.6714
HCC1500	CTRP2	4.1715	5.3968	3.9767	6.5207
HMC-1-8	CTRP2	4.2179	4.8628	4.1847	5.6202
Hs 578Bst	CTRP2	4.2429	6.0991	3.7585	7.1816
CAMA-1	CTRP2	4.2587	5.0916	4.1736	5.5336
JIMT-1	CTRP2	4.347	4.9306	4.3111	4.7696
MDA-MB-415	CTRP2	4.3666	5.3932	4.187	5.9825
HCC1937	CTRP2	4.4049	5.3837	4.2315	4.8938
SK-BR-3	CTRP2	4.43	6.041	3.9729	5.8494
EFM-192A	CTRP2	4.4455	5.104	4.3736	4.244
HCC1143	CTRP2	4.4569	5.9401	4.0461	5.4875
T-47D	CTRP2	4.4775	7.9911	3.0755	9.4381
BT-20	CTRP2	4.4868	8.9307	2.619	11.3142
BT-549	CTRP2	4.498	5.2596	4.3781	4.0738
CAL-120	CTRP2	4.5417	5.0963	4.4808	3.564
HCC1428	CTRP2	4.5609	4.9453	4.5401	3.2924
ZR-75-30	CTRP2	4.5662	5.268	4.4481	3.6154
CAL-85-1	CTRP2	4.5675	7.969	3.1678	8.8584
BT-474	CTRP2	4.5821	5.1272	4.5151	3.318
HCC1419	CTRP2	4.6018	5.1825	4.5177	3.2509
HDQ-P1	CTRP2	4.6066	5.205	4.5148	3.2482
MDA-MB-231	CTRP2	4.6331	5.4972	4.4237	3.5294
CAL-51	CTRP2	4.7418	5.5953	4.4888	2.9936
ZR-75-1	CTRP2	4.7796	5.2583	4.6782	2.1409
HCC202	CTRP2	4.8771	6.2844	4.28	3.5514
MDA-MB-157	CTRP2	5.0153	6.4334	4.3255	3.0786
MDA-MB-453	CTRP2	6.5685	22.8129	-2.6038	24.3249
MDA-MB-361	CTRP2	9.2843	34.5813	-6.3566	27.1303
BT 248	CTRP2	1.7054	4.6689	1.4957	22.9691
BT 239	CTRP2	2.8061	5.1967	2.5585	15.7836
BT 231	CTRP2	3.3793	6.4461	2.7175	13.5559
BT 286	CTRP2	3.5061	5.7037	3.1486	11.545
BT 228	CTRP2	3.5229	5.5187	3.2339	11.1754
BT 216	CTRP2	3.5514	5.4171	3.2999	10.8461
BT 428	CTRP2	3.6056	5.5034	3.3286	10.5818
BT 232	CTRP2	3.6573	4.8657	3.5754	9.5238
BT 131	CTRP2	3.7289	5.2459	3.549	9.4021
BT 422	CTRP2	3.7717	5.4794	3.5164	9.3987
BT 330	CTRP2	3.7728	4.8511	3.7042	8.7081
BT 359	CTRP2	3.8	6.0778	3.3114	10.1081
BT 416	CTRP2	3.825	7.5191	2.6865	12.5433
BT 172	CTRP2	3.88	4.8457	3.8219	7.9575
BT 187	CTRP2	3.951	6.3701	3.3406	9.5957
BT 340	CTRP2	3.9866	6.0286	3.5265	8.7676
BT 245	CTRP2	3.993	5.8781	3.5966	8.4759
BT 159	CTRP2	4.0311	4.9663	3.9589	7.0016
BT 440	CTRP2	4.1273	5.4415	3.9127	6.8882
BT147	CTRP2	4.1703	5.1292	4.066	6.1912
BT 333	CTRP2	4.1815	5.8268	3.8148	7.1182
BT 504	CTRP2	4.2078	5.5785	3.9453	6.5394
BT 145	CTRP2	4.2416	5.4565	4.0292	6.1233
BT 320	CTRP2	4.3023	4.9013	4.2686	5.0599
BT 139	CTRP2	4.3282	9.504	2.1928	13.4078
BT 224	CTRP2	4.3838	4.8874	4.3594	4.4845
BT 482	CTRP2	4.4225	5.0092	4.375	4.3085
BT 444	CTRP2	4.4667	4.9753	4.4314	3.9708
BT 179	CTRP2	4.5225	4.8736	4.5107	3.5171
BT 328	CTRP2	4.5624	4.9438	4.5421	3.2808
BT164	CTRP2	4.6132	4.9256	4.6001	2.9172
BT 498	CTRP2	4.8149	5.8273	4.4483	2.9867

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	4.2387	4.8764	4.2046	5.4846

Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CAS-1	CTRP2	3.2419	4.437	3.2038	13.004
LN-18	CTRP2	3.6508	4.0352	3.6507	9.2849
SNU-466	CTRP2	3.8632	4.6821	3.8331	7.9717
LN-229	CTRP2; CTRP1	3.9671	4.9361	3.8985	7.5038
GOS-3	CTRP2	4.2715	9.0929	2.3448	12.9109
SNU-1105	CTRP2	4.3441	13.6101	0.1648	20.975
TM-31	CTRP2	4.3735	4.8415	4.3559	4.5294
SF539	CTRP2	4.3806	7.6839	3.1375	9.395
SF268	CTRP2	4.3871	8.4676	2.7583	10.9526
M059K	CTRP2	4.3881	4.9011	4.3616	4.4629
NMC-G1	CTRP2	4.3922	4.9794	4.3493	4.4937
GB-1	CTRP2	4.4211	8.8127	2.6186	11.4572
SNB-75	CTRP2	4.4282	5.8617	4.0528	5.533
ONS-76	CTRP2	4.4544	6.2188	3.9143	6.0265
U-251MG	CTRP2	4.4696	12.4272	0.8637	18.2707
Daoy	CTRP2	4.4697	5.3042	4.3311	4.332
KNS-60	CTRP2	4.4833	4.9061	4.4635	3.8056
SW1783	CTRP2	4.4852	5.5157	4.2627	4.5535
42-MG-BA	CTRP2	4.4996	5.251	4.3829	4.0513
A-172	CTRP2	4.5011	5.1596	4.4165	3.9211
T98G	CTRP2	4.5054	14.9492	-0.364	22.3226
U-118MG	CTRP2	4.5101	5.1369	4.4336	3.8316
KNS-81	CTRP2	4.5181	5.0747	4.4615	3.7054
SF126	CTRP2	4.5278	5.9776	4.0994	5.0962
GaMG	CTRP2	4.5378	5.8446	4.1708	4.7832
GMS-10	CTRP2	4.5685	4.9015	4.556	3.213
YKG-1	CTRP2	4.5843	4.9745	4.5595	3.1505
DBTRG-05MG	CTRP2	4.5967	5.1148	4.5349	3.202
CCF-STTG1	CTRP2	4.599	4.9349	4.5832	3.0212
SNU-626	CTRP2	4.6089	5.1697	4.5298	3.1852
SF295	CTRP2	4.6212	5.513	4.4047	3.6356
DK-MG	CTRP2	4.645	5.0358	4.6109	2.7799
SW1088	CTRP2	4.7472	6.325	4.1422	4.4074
Becker	CTRP2	4.7495	5.6239	4.4831	2.998
U-87MG ATCC	CTRP2	4.8445	5.5695	4.601	2.2891
KALS-1	CTRP2	5.0633	6.3284	4.418	2.5966
8-MG-BA	CTRP2	5.2057	6.7759	4.3091	2.7928
SNU-489	CTRP2	5.3121	6.6465	4.454	2.0102
SNU-201	CTRP2	5.3515	7.7375	3.9445	4.0635
SNU-738	CTRP2	5.5467	7.3417	4.2826	2.3526
YH-13	CTRP2	5.9516	9.6569	3.4435	5.1662
KG-1-C	CTRP2	11.7193	38.1949	-6.3512	24.1649

Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHUEM-2	CTRP2; CTRP1	3.7182	4.6462	3.6843	9.0385
RL95-2	CTRP2	3.9867	5.1851	3.8489	7.5345
HEC-1-B	CTRP2	4.1641	11.3844	1.1139	18.0076
HEC-6	CTRP2	4.4055	5.0131	4.3554	4.431
HEC-1-A	CTRP2	4.4558	5.0536	4.3995	4.1184
EN	CTRP2	4.4572	4.9397	4.4288	4.0097
KLE	CTRP2	4.4598	5.4905	4.2467	4.6845
MFE-296	CTRP2	4.4604	8.7378	2.6909	11.0728
JHUEM-1	CTRP2	4.4641	4.86	4.4502	3.9133
AN3-CA	CTRP2	4.5197	8.5759	2.8243	10.3918
HEC-59	CTRP2	4.6037	7.0223	3.6678	6.697
HEC-151	CTRP2	4.6974	5.3263	4.5638	2.8084
MFE-319	CTRP2	4.7126	5.2937	4.5932	2.6528
HEC-265	CTRP2	4.7309	5.4679	4.5365	2.8287
HEC-251	CTRP2	4.9542	7.0307	3.9751	4.6716
EFE-184	CTRP2	5.1913	7.4564	3.9585	4.2885
HEC-50B	CTRP2	5.2002	6.2616	4.5603	1.7534
ESS-1	CTRP2	5.2368	6.3916	4.5237	1.8444
HEC-108	CTRP2	5.4427	7.0076	4.3717	2.1453
Ishikawa (Heraklio) 02 ER-	CTRP2	5.6494	6.7473	4.6287	0.8681

Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
UO-31	CTRP2	3.8809	7.5002	2.7499	12.1507
TUHR14TKB	CTRP2	4.0894	6.967	3.205	20.8576
BFTC-909	CTRP2	4.141	5.377	3.9512	6.7037
A-498	CTRP2	4.2769	5.0063	4.2169	5.322
VMRC-RCW	CTRP2	4.2925	7.7965	3.0006	10.1601
Caki-2	CTRP2	4.35	4.9005	4.3204	4.7278
KMRC-20	CTRP2	4.3742	5.0218	4.3191	4.6571
TUHR4TKB	CTRP2	4.4424	5.0765	4.3783	4.236
CAL-54	CTRP2	4.4496	8.0456	3.0233	9.7162
SNU-1272	CTRP2	4.4705	5.1213	4.3956	4.0887
KMRC-2	CTRP2	4.5139	4.8903	4.499	3.5849
KMRC-1	CTRP2	4.5881	4.9681	4.565	3.1192
TUHR10TKB	CTRP2	4.6422	5.0685	4.5986	2.8329
769-P	CTRP2	4.7132	6.0929	4.2237	4.147
VMRC-RCZ	CTRP2	4.7848	11.4021	1.6467	14.6415
OS-RC-2	CTRP2	5.2061	7.0951	4.1505	3.4567
ACHN	CTRP2	5.4101	6.7537	4.472	1.7849
RCC10RGB	CTRP2	5.4515	8.1691	3.807	5.1673
Caki-1	CTRP2	7.2883	14.0942	2.2253	8.0758
786-O	CTRP2	7.394	14.2586	2.2177	7.9583

Cancer Drug Sensitivity Data Curated from 50 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H508	CTRP1	1.1204	6.281	0.3743	53.9537
SW48	CTRP2	3.0871	7.0572	2.1529	16.5406
HT115	CTRP2; CTRP1	3.2461	4.1583	3.2357	12.1004
T84	CTRP2	3.3043	5.7913	2.8995	13.061
OUMS-23	CTRP2	3.3144	4.5665	3.2621	11.7035
SNU-C1	CTRP2	3.6465	8.4026	2.0943	15.3645
RCM-1 [Human ESC]	CTRP2; CTRP1	3.6793	4.4855	3.6626	9.2384
NCI-H747	CTRP2	3.7806	6.0823	3.2892	10.2467
LoVo	CTRP2; CTRP1	3.8568	5.7754	3.4999	9.3089
SK-CO-1	CTRP2	3.8653	4.9203	3.7893	8.1185
LS180	CTRP2	3.981	4.986	3.8993	7.3686
HT-29	CTRP2; CTRP1	4.0253	4.9067	3.9685	7.075
SNU-81	CTRP1	4.0556	4.9652	3.9881	14.8348
SNU-C5	CTRP2; CTRP1	4.1175	5.3005	3.9567	6.8403
LS513	CTRP2	4.1302	5.2238	3.9925	6.581
SNU-C2A	CTRP2	4.1701	7.2471	3.1504	9.8264
HCT 116	CTRP2; CTRP1	4.1788	5.0321	4.1056	6.1129
CL-40	CTRP1	4.2036	5.1164	4.1091	12.9315
COLO 678	CTRP2; CTRP1	4.2132	4.9736	4.1578	5.8202
SNU-175	CTRP1	4.2493	12.0272	0.879	33.0532
HT-55	CTRP2; CTRP1	4.251	4.9681	4.2002	5.5528
SNU-61	CTRP2; CTRP1	4.2809	5.8543	3.9116	6.5639
RKO	CTRP2; CTRP1	4.2851	5.135	4.1925	5.4769
KM12	CTRP2; CTRP1	4.3289	5.1772	4.2271	5.2196
MDST8	CTRP2; CTRP1	4.3632	4.8724	4.3412	4.7053
CL-34	CTRP1	4.3869	5.1559	4.297	10.2831
HCT 15	CTRP2	4.3888	5.0427	4.3294	4.5752
SNU-503	CTRP2	4.4029	8.4137	2.7992	10.7485
CW-2	CTRP2; CTRP1	4.403	5.0266	4.3516	4.544
CCK-81	CTRP2	4.4076	5.7336	4.0887	5.4432
SNU-407	CTRP2	4.4276	5.1428	4.342	4.4129
COLO205	CTRP2	4.4527	4.9409	4.4237	4.0415
CL-11	CTRP2	4.4588	5.3243	4.3118	4.4366
COLO201	CTRP2	4.4745	5.0084	4.4319	3.9448
SNU-C4	CTRP2; CTRP1	4.4977	4.9623	4.4699	3.8308
SW948	CTRP2; CTRP1	4.5002	4.9244	4.4799	3.7878
LS123	CTRP2; CTRP1	4.5078	5.0155	4.4687	3.8034
SNU-1040	CTRP1	4.5291	4.9539	4.5056	7.7407
HCT 8	CTRP2; CTRP1	4.5326	4.9898	4.5018	3.6091
LS411N	CTRP2	4.5625	5.0992	4.5026	3.4222
C2BBe1	CTRP2	4.5654	5.9361	4.1558	4.7756
NCI-H716	CTRP2	4.6117	5.309	4.4806	3.3642
SW1417	CTRP2	4.613	5.2036	4.5222	3.2017
GP2d	CTRP2	4.6751	5.2237	4.5813	2.8017
DLD-1	CTRP2	4.6982	5.2912	4.5792	2.7462
HCC-56	CTRP2	4.8547	5.3226	4.7271	1.7516
COLO 320	CTRP2; CTRP1	4.8968	7.3556	3.7728	6.6183
SW620	CTRP2; CTRP1	5.1708	7.599	3.8809	4.7351
SW480	CTRP1	5.1836	7.6514	3.865	10.2276
LS1034	CTRP2	8.6927	22.4812	-0.8524	16.4831

Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-182	CTRP2	2.1696	5.4349	1.7923	20.486
Li-7	CTRP2	3.5885	5.3858	3.3507	10.5489
JHH-1	CTRP2	4.0961	5.4714	3.868	7.1461
Hep-G2	CTRP2; CTRP1	4.103	5.3164	3.9355	6.9616
SNU-761	CTRP2	4.1204	6.6293	3.3933	8.9571
Hep 3B2.1-7	CTRP2	4.226	5.1847	4.1094	5.8665
HuH-1	CTRP2	4.2975	4.9875	4.2441	5.1612
JHH-2	CTRP2	4.3972	5.0346	4.3407	4.509
JHH-4	CTRP2	4.4155	11.4464	1.3053	16.7373
SNU-398	CTRP2	4.4773	9.4006	2.3774	12.3315
JHH-5	CTRP2	4.4938	5.0241	4.449	3.8243
SNU-387	CTRP2	4.4993	5.2034	4.3996	3.9893
SNU-475	CTRP2	4.5674	4.9411	4.548	3.2445
SNU-886	CTRP2	4.5759	5.4965	4.3651	3.9108
SK-HEP-1	CTRP2	4.5927	5.1558	4.5171	3.2796
SNU-423	CTRP2	4.636	5.2778	4.5187	3.1508
PLC/PRF/5	CTRP2	4.692	5.4847	4.4895	3.1157
JHH-6	CTRP2	4.8329	5.237	4.7427	1.7462
SNU-449	CTRP2	9.9415	24.2806	-0.8623	14.8036

Cancer Drug Sensitivity Data Curated from 136 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
DMS 79	CTRP2	1.7925	21.8714	-6.2122	39.1432
NCI-H211	CTRP2	2.6546	3.9755	2.6324	15.9958
DMS 454	CTRP2	2.7931	5.6282	2.4065	16.3817
Calu-3	CTRP2	2.8947	4.1268	2.871	14.4014
NCI-H1666	CTRP2	2.9094	5.8333	2.4597	15.8471
HCC95	CTRP2	3.2807	4.1616	3.2709	11.7829
NCI-H2342	CTRP2; CTRP1	3.3653	4.7426	3.2864	11.5428
NCI-H69	CTRP2	3.4588	4.864	3.3598	10.906
NCI-H596	CTRP1	3.5273	4.6946	3.471	22.2925
NCI-H2081	CTRP1	3.6363	5.2249	3.458	21.67
NCI-H2106	CTRP2	3.7046	5.2312	3.5273	9.5543
NCI-H1581	CTRP2	3.7365	4.8442	3.6663	8.9555
LC-1F	CTRP2	3.7387	6.242	3.178	10.7939
NCI-H1105	CTRP2; CTRP1	3.7912	4.8247	3.7316	8.6418
NCI-H1734	CTRP2	3.8066	5.4313	3.5711	9.0928
HCC1588	CTRP2	3.8128	6.4792	3.1512	10.7055
HCC44	CTRP2	3.8187	5.8877	3.4096	9.6755
NCI-H1693	CTRP2	3.9156	5.7483	3.5681	8.7973
T3M-10	CTRP2; CTRP1	3.9556	5.0019	3.87	7.6408
NCI-H2087	CTRP2	3.9769	7.1702	2.9993	10.9053
MOR/CPR	CTRP2	3.9849	4.6666	3.9652	7.1252
NCI-H2405	CTRP2	3.9931	4.9427	3.9232	7.2461
NCI-H2291	CTRP2	3.9936	5.5707	3.7206	7.9958
CAL-12T	CTRP2; CTRP1	4.049	4.9808	3.9771	6.9711
BEN	CTRP2	4.0638	4.8085	4.0282	6.6545
HCC4006	CTRP2; CTRP1	4.0958	5.1763	3.9736	6.8421
NCI-H2122	CTRP2; CTRP1	4.1361	5.1876	4.0139	6.5742
HCC2935	CTRP2; CTRP1	4.1496	5.373	3.966	6.7132
HCC1833	CTRP2; CTRP1	4.1504	5.8474	3.7794	7.4282
NCI-H1876	CTRP1	4.16	5.6912	3.8543	15.2606
NCI-H841	CTRP2; CTRP1	4.1751	5.3114	4.0153	6.4549
NCI-H510A	CTRP2	4.1833	6.3298	3.5938	7.9924
HCC2279	CTRP2	4.1843	7.8543	2.871	10.941
NCI-H526	CTRP2	4.2184	4.9688	4.1625	5.6968
SK-LU-1	CTRP2; CTRP1	4.2267	5.4169	4.0328	6.2415
NCI-H1155	CTRP2	4.2629	5.4812	4.0423	6.0137
NCI-H1836	CTRP1	4.2671	5.3239	4.1103	12.5218
COLO 699	CTRP2; CTRP1	4.2746	4.9372	4.2328	5.3638
EKVX	CTRP2	4.2848	8.5625	2.6181	11.7574
NCI-H1694	CTRP2; CTRP1	4.2863	5.0165	4.2269	5.3484
NCI-H2009	CTRP2	4.2924	5.4385	4.0903	5.7477
NCI-H1838	CTRP2	4.3117	5.2236	4.1895	5.3182
NCI-H1755	CTRP2; CTRP1	4.3177	5.3464	4.1566	5.515
DMS 273	CTRP2	4.3179	6.4066	3.6922	7.2611
Sq-1	CTRP1	4.3233	5.1901	4.2168	11.3197
NCI-H322	CTRP2	4.3258	9.0206	2.4297	12.4432
HCC1171	CTRP2	4.3261	9.5736	2.1565	13.5604
HCC366	CTRP2	4.3341	9.3466	2.276	13.0556
SW1271	CTRP2	4.3387	6.4057	3.713	7.126
DMS 53	CTRP2	4.3481	5.5231	4.1159	5.4956
EBC-1	CTRP2	4.3535	6.6266	3.6232	7.4562
NCI-H2126	CTRP2	4.3568	9.2162	2.361	12.6577
NCI-H1435	CTRP2	4.3571	6.6931	3.595	7.5628
NCI-H2172	CTRP2; CTRP1	4.3692	4.8901	4.3447	4.674
NCI-H2023	CTRP2; CTRP1	4.3746	4.9928	4.329	4.7121
HOP-62	CTRP2	4.3749	8.4937	2.7344	11.0783
HCC1359	CTRP1	4.3885	4.8721	4.3685	9.7235
NCI-H1373	CTRP2	4.3955	7.103	3.4345	8.1328
COR-L88	CTRP2	4.3959	5.2049	4.2872	4.7093
HOP-92	CTRP2	4.4	6.2896	3.8277	6.511
HCC827	CTRP2; CTRP1	4.4021	5.113	4.3266	4.6371
NCI-H358	CTRP2	4.4072	5.4344	4.214	4.9545
NCI-H2196	CTRP2	4.4072	5.9616	3.9864	5.8521
COR-L95	CTRP2	4.4073	5.1289	4.3243	4.5385
Lu-65	CTRP2	4.4155	5.3529	4.2547	4.7757
NCI-H1944	CTRP2	4.4201	5.1669	4.326	4.4943
NCI-H292	CTRP2	4.4225	5.3591	4.2597	4.7371
HCC15	CTRP2; CTRP1	4.4229	5.464	4.2237	4.965
HCC2108	CTRP2; CTRP1	4.4231	5.0044	4.3791	4.3838
RERF-LC-A1	CTRP2	4.4236	7.8177	3.1116	9.4065
NCI-H23	CTRP2	4.4324	12.0197	1.0345	17.7218
NCI-H727	CTRP2	4.4375	5.735	4.1188	5.2464
NCI-H647	CTRP2	4.4433	6.334	3.8491	6.3189
NCI-H1184	CTRP2	4.4451	5.6547	4.1616	5.0571
NCI-H1793	CTRP2	4.4628	5.1911	4.3644	4.2267
NCI-H446	CTRP2	4.4662	5.2079	4.3623	4.2247
NCI-H1915	CTRP2	4.4805	5.1074	4.4108	4.0031
PC-14	CTRP2	4.4845	5.4897	4.2729	4.5157
SHP-77	CTRP2	4.4871	5.1107	4.4169	3.9611
NCI-H661	CTRP2	4.5021	6.1086	4.0128	5.5105
RERF-LC-MS	CTRP2	4.5135	5.1218	4.4422	3.7897
HCC1195	CTRP2; CTRP1	4.5153	5.0832	4.4589	3.8158
NCI-H520	CTRP2	4.5161	5.1563	4.4339	3.8127
NCI-H2228	CTRP2	4.5177	5.6953	4.2182	4.644
NCI-H1781	CTRP1	4.5229	5.0787	4.4684	8.0668
Lu-99	CTRP2	4.5229	5.0258	4.4803	3.6227
ChaGo-K-1	CTRP2	4.5311	5.3107	4.3943	3.919
NCI-H522	CTRP2	4.5367	5.2631	4.4183	3.8118
Calu-6	CTRP2	4.5402	5.0426	4.4946	3.5186
NCI-H1869	CTRP2	4.5414	5.1754	4.4549	3.6607
NCI-H1355	CTRP2	4.5431	5.6808	4.2505	4.4501
HARA [Human squamous cell lung carcinoma]	CTRP2	4.5448	5.155	4.4654	3.6119
NCI-H2085	CTRP2	4.5467	5.5198	4.3249	4.146
NCI-H2286	CTRP2	4.5503	5.217	4.4499	3.6536
NCI-H889	CTRP2	4.5661	5.7974	4.2207	4.5115
COR-L23	CTRP1	4.5687	4.9968	4.5396	7.2183
NCI-H2444	CTRP2	4.5808	4.9653	4.5577	3.1679
LUDLU-1	CTRP2	4.5978	5.1425	4.5271	3.2277
SBC-5	CTRP2	4.6116	5.0406	4.5731	3.0179
NCI-H441	CTRP2; CTRP1	4.6175	6.0453	4.1625	4.7116
LOU-NH91	CTRP2	4.6369	5.2573	4.5276	3.1138
NCI-H650	CTRP2	4.6475	5.1381	4.5825	2.8766
NCI-H3255	CTRP1	4.649	5.3876	4.4929	7.0984
NCI-H1573	CTRP2	4.6552	5.342	4.513	3.1197
COR-L105	CTRP2	4.6593	6.15	4.1451	4.5952
LCLC-97TM1	CTRP2	4.6621	5.6509	4.384	3.614
NCI-H2170	CTRP2	4.6758	5.5478	4.4447	3.3361
LXF 289	CTRP2	4.6875	8.8708	2.8261	10.031
NCI-H1623	CTRP2	4.6926	5.5348	4.4675	3.2022
NCI-H1651	CTRP2	4.6984	57.492	-21.4683	42.6639
LCLC-103H	CTRP2	4.726	5.4183	4.5537	2.7728
RERF-LC-Ad2	CTRP2	4.7286	5.2221	4.6389	2.4322
EPLC-272H	CTRP2	4.7306	5.5119	4.5162	2.9106
NCI-H2073	CTRP1	4.7503	5.3443	4.6168	5.4783
NCI-H1563	CTRP2	4.7541	8.0429	3.2968	7.9255
DMS 114	CTRP2	4.756	5.5571	4.5207	2.8296
NCI-H460	CTRP2; CTRP1	4.8062	5.6471	4.5345	2.7432
NCI-H1792	CTRP2	4.841	11.562	1.6146	14.6537
A-549	CTRP2	4.8435	5.8012	4.4879	2.7582
NCI-H1568	CTRP2	4.865	11.2339	1.7989	13.8766
RERF-LC-Ad1	CTRP2	4.8675	14.4161	0.2103	19.7254
NCI-H838	CTRP2	4.8718	5.6964	4.5653	2.3735
NCI-H2030	CTRP2; CTRP1	4.9814	6.7732	4.1363	4.0264
NCI-H1395	CTRP2	5.1397	6.7681	4.2606	3.1151
NCI-H1299	CTRP2	5.1512	6.5004	4.4034	2.4953
NCI-H1339	CTRP2	5.1835	7.2878	4.0364	3.9759
HCC1438	CTRP2	5.3212	13.575	1.0075	16.018
NCI-H226	CTRP2	5.3666	7.3884	4.1288	3.2695
NCI-H196	CTRP2	5.4825	8.2523	3.7893	4.4881
KNS-62	CTRP2	5.6274	8.4405	3.8044	4.1891
Calu-1	CTRP2	5.6818	15.2888	0.4433	17.3428
NCI-H2110	CTRP2; CTRP1	6.3113	9.0574	3.982	2.6011
NCI-H1650	CTRP2	6.329	12.8279	2.1644	9.7609
HCC78	CTRP2	6.3718	9.3658	3.8643	2.9073
LK2	CTRP2	12.4848	33.1859	-3.4133	17.9532
Hs 888.Lu	CTRP2	4.6876	5.4699	4.4916	3.1189

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-CH1	CTRP2	0.8195	2.8823	-3.6026	0.2405

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	3.356	6.4462	2.6932	13.7133
COV434	CTRP2; CTRP1	2.864	4.1452	2.8376	14.6975
OVK18	CTRP2; CTRP1	3.3148	4.7327	3.2336	11.8865
COV644	CTRP2; CTRP1	3.7268	21.6279	-4.3603	32.9383
RMUG-S	CTRP1	3.8209	5.8531	3.431	20.7359
TYK-nu	CTRP2; CTRP1	4.0133	5.0229	3.9275	7.258
A2780	CTRP2	4.0373	5.9811	3.5993	8.3473
OV-90	CTRP2; CTRP1	4.1071	5.8193	3.7459	7.6747
Kuramochi	CTRP2	4.2792	6.3971	3.6584	7.4934
Caov-3	CTRP2; CTRP1	4.2839	4.892	4.2522	5.2665
ONCO-DG-1	CTRP2	4.2931	5.1684	4.1875	5.3801
RMG-I	CTRP2; CTRP1	4.2996	5.9086	3.9071	6.533
SNU-119	CTRP2	4.3293	6.3625	3.7241	7.104
JHOM-1	CTRP2; CTRP1	4.3482	4.8429	4.3298	4.7926
OV56	CTRP2	4.3805	4.8409	4.3636	4.4804
COV362	CTRP2; CTRP1	4.4023	4.9821	4.3618	4.51
OVCAR-5	CTRP2	4.4036	7.521	3.2386	8.9247
JHOS-2	CTRP2	4.4219	9.3289	2.3636	12.5066
OVSAHO	CTRP2	4.4404	5.1641	4.349	4.3492
OAW28	CTRP2	4.4548	8.1973	2.9531	9.9965
OC 314	CTRP2	4.4955	5.0319	4.4487	3.8204
OVTOKO	CTRP2	4.5177	5.8094	4.1668	4.8496
OV7	CTRP1	4.6056	5.404	4.4406	7.7868
IGROV-1	CTRP2	4.6255	5.8188	4.2699	4.1658
MCAS	CTRP2	4.7029	5.4535	4.5145	2.9882
FU-OV-1	CTRP2	4.7031	8.7962	2.877	9.7863
TOV-112D	CTRP2	4.7366	12.5317	1.0413	17.0583
SNU-8	CTRP2	4.7471	5.2122	4.6626	2.2899
OAW42	CTRP2; CTRP1	4.7549	5.3466	4.6205	2.5258
SK-OV-3	CTRP2	4.7626	5.4083	4.5954	2.5124
HEY A8	CTRP2	4.7926	5.7037	4.487	2.8791
DOV13	CTRP2	4.8493	6.0819	4.3552	3.2968
JHOC-5	CTRP2; CTRP1	4.9047	11.6861	1.616	14.5924
OVCAR-8	CTRP2	4.9414	6.0541	4.4513	2.6991
OVCAR-4	CTRP2	4.9829	7.6919	3.669	5.9009
SNU-840	CTRP2; CTRP1	5.0277	13.242	0.9413	16.9042
OVISE	CTRP2	5.0636	6.0266	4.5692	1.9607
ES2	CTRP2	5.1103	6.4024	4.4195	2.5024
EFO-27	CTRP2; CTRP1	5.135	7.0397	4.1311	3.7517
TOV-21G	CTRP2	5.1739	6.2356	4.553	1.8286
EFO-21	CTRP2	6.2614	8.1361	4.3562	1.2236

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Aska-SS	CTRP2	4.2908	5.3513	4.1216	5.6331
Yamato-SS	CTRP2	4.4523	5.0027	4.4091	4.0945
TTC-709	CTRP2	3.116	6.3146	2.4953	15.1325
Rh41	CTRP2	3.828	5.7288	3.4829	9.3674
A-204	CTRP2	4.1131	7.1767	3.129	10.0489
RD	CTRP2	4.1335	10.5149	1.5173	16.5327
Tm87-16	CTRP2	4.3535	5.1403	4.2622	4.9263
G-401	CTRP2	4.3598	5.9305	3.9526	6.1079
HT-1080	CTRP2; CTRP1	4.4245	4.927	4.3976	4.3144
Hs 729.T	CTRP2	4.4374	4.9524	4.4046	4.1569
GCT	CTRP2	4.4397	5.1712	4.346	4.3624
BT-16	CTRP2	4.4571	5.0144	4.4114	4.0716
KYM-1	CTRP2	4.4634	5.7632	4.1326	5.1246
TE 441.T	CTRP2	4.4786	5.0233	4.4326	3.9299
MES-SA	CTRP2	4.4882	5.0462	4.4369	3.8851
BT-12	CTRP2	4.4988	4.8411	4.4897	3.6654
Rh18	CTRP2	4.5828	5.1548	4.5067	3.347
SW982	CTRP2	4.6115	5.101	4.5554	3.0824
RKN	CTRP2	5.0456	5.7955	4.6699	1.5719
SK-LMS-1	CTRP2	5.1953	7.2279	4.0757	3.7895
G-402	CTRP2	8.1279	16.7992	1.4955	9.6431
SK-UT-1	CTRP2	8.7908	19.2016	0.7918	11.2088

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SYO-1	CTRP2	4.3874	5.5375	4.1512	5.2517
P-STS	CTRP2	4.4461	5.1666	4.3544	4.3128
H-STS	CTRP2	4.5578	4.8862	4.5467	3.2796

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H2452	CTRP2	4.2393	7.7631	2.9671	10.4192
IST-Mes1	CTRP2	4.3064	8.6233	2.608	11.7512
NCI-H28	CTRP2	4.3326	5.4545	4.1269	5.4957
MSTO-211H	CTRP2	4.4496	5.8071	4.0991	5.2937
MPP 89	CTRP2	4.5987	5.2646	4.4841	3.3871
NCI-H2052	CTRP2	4.7578	6.6786	3.9777	5.0694
ACC-MESO-1	CTRP2	5.3128	6.7964	4.3808	2.312
JL-1	CTRP2	10.9935	28.2234	-2.0408	16.5779

Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
22Rv1	CTRP2	4.1039	6.7864	3.3039	9.3593
VCaP	CTRP2	4.4376	5.2326	4.3226	4.456
LNCaP clone FGC	CTRP2	4.8102	6.0058	4.3568	3.3763
PaCa-3	CTRP2	5.1191	5.8811	4.6866	1.3658
DU145	CTRP2	5.3902	7.3056	4.1874	2.9872

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-15	CTRP2	4.1466	5.255	3.9999	6.5052
A-253	CTRP2	4.551	5.7769	4.215	4.5724

Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-16	CTRP2	2.266	4.9138	2.0469	19.2725
GSS	CTRP2	2.6887	3.8929	2.674	15.7433
SNU-620	CTRP2	3.1274	4.066	3.1179	12.8028
Fu97	CTRP2	3.3251	6.0477	2.8232	13.2942
23132/87	CTRP2	3.6768	4.9342	3.5805	9.4453
SNU-719	CTRP2	3.6832	5.1718	3.5222	9.6365
KE-39	CTRP2	3.7011	6.229	3.1445	11.0255
SNU-5	CTRP2	3.7268	4.738	3.6771	8.9481
AGS	CTRP2	3.8032	4.8295	3.7419	8.48
NCI-N87	CTRP2	3.8537	7.1141	2.904	11.593
NUGC-4	CTRP2	3.867	5.4059	3.6453	8.6405
HGC-27	CTRP2	3.9443	6.9746	3.0586	10.7448
HuG1-N	CTRP2	4.0046	7.4734	2.8828	11.3128
ECC10	CTRP2	4.0418	5.5919	3.7638	7.6962
GSU	CTRP2	4.1047	4.7571	4.0806	6.342
NUGC-3	CTRP2	4.1716	5.3264	4.0023	6.4237
SNU-1	CTRP2	4.2604	6.5785	3.5552	7.9576
SNU-601	CTRP2	4.2608	8.0915	2.827	22.8246
SNU-668	CTRP2	4.38	4.9226	4.3486	4.5341
Hs 746.T	CTRP2	4.4557	4.9586	4.4231	4.0345
KATO III	CTRP2	4.4933	6.029	4.0414	5.4159
MKN1	CTRP2	4.5336	5.0875	4.4746	3.8685
LMSU	CTRP2	4.5478	5.0231	4.5081	3.4467
MKN7	CTRP2	4.5763	5.1051	4.5157	3.3329
MKN74	CTRP2	4.6095	5.3295	4.47	3.4111
SH-10-TC	CTRP2	4.65	5.2077	4.5605	2.952
ECC12	CTRP2	5.3481	6.6303	4.4881	1.8132
IM95	CTRP2	5.4586	23.5454	-3.8632	28.8169
MKN45	CTRP2	6.2586	7.369	4.6717	0.2916
SNU-216	CTRP2	10.115	26.0961	-1.6142	16.6112
SNU-685	CTRP2	4.6014	5.0431	4.5613	3.0915
SNG-M	CTRP2	4.9762	6.3045	4.3566	3.0254
SNU-1077	CTRP2	5.1526	7.1583	4.0762	3.8656

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TT	CTRP2	3.7175	4.9966	3.6091	9.2178
8305C	CTRP2	4.2383	5.0167	4.172	5.6015
FTC-238	CTRP2	4.3052	4.8862	4.2747	5.0293
8505C	CTRP2	4.3594	6.7118	3.5884	7.5847
BHT-101	CTRP2	4.3916	5.1558	4.2987	4.6792
B-CPAP	CTRP2	4.3988	5.0393	4.3413	4.5019
SW579	CTRP2	4.4138	4.8839	4.3925	4.2738
ML-1 [Human leukemia]	CTRP2	4.5263	5.3476	4.3747	4.0072
CGTH-W-1	CTRP2	5.0627	5.9579	4.6028	1.8209
FTC-133	CTRP2	5.4051	6.8413	4.4259	1.9807
TT2609-C02	CTRP2	5.6646	8.639	3.7341	4.4198

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Detroit 562	CTRP2	2.7887	4.5328	2.7011	15.3278
SNU-1214	CTRP2	3.4091	4.7083	3.339	11.1352
BHY	CTRP2	3.8786	5.005	3.7827	8.1009
YD-10B	CTRP2	4.0535	5.0329	3.9662	6.9066
HSC-3	CTRP2	4.1032	5.4108	3.8981	7.0121
SNU-899	CTRP2	4.2387	5.2241	4.1102	5.8261
CAL-27	CTRP2	4.2555	4.9752	4.2013	5.4436
SCC-25	CTRP2	4.3112	5.6827	4.0109	6.0043
SNU-46	CTRP2	4.3805	5.7447	4.056	5.6433
CAL-33	CTRP2	4.399	5.2572	4.2723	4.7556
SNU-1076	CTRP2	4.4408	5.1773	4.3451	4.3627
PE/CA-PJ34 (clone C12)	CTRP2	4.4684	8.9568	2.5896	11.4753
YD-8	CTRP2	4.4782	8.7996	2.6763	11.0952
BICR 18	CTRP2	4.5079	5.0632	4.4537	3.7646
SCC-4	CTRP2	4.5375	5.0605	4.4867	3.555
PE/CA-PJ15	CTRP2	4.5445	5.0378	4.5006	3.4839
BICR 22	CTRP2	4.5459	5.0453	4.5001	3.4813
PE/CA-PJ41 (clone D2)	CTRP2	4.6081	4.9655	4.5872	2.9783
SCC-9	CTRP2	4.626	11.589	1.4171	15.8637
BICR 31	CTRP2	4.7341	5.5712	4.4924	2.9978
BICR 16	CTRP2	4.7357	5.6867	4.44	3.2066
HSC-4	CTRP2	4.8076	5.5086	4.5941	2.4055
FaDu	CTRP2	4.827	5.4064	4.6609	2.0873
HSC-2	CTRP2	4.8378	5.8363	4.4654	2.8643
SNU-1041	CTRP2	5.0013	6.5695	4.2457	3.4414
SNU-1066	CTRP2	5.06	5.9327	4.6132	1.7825
BICR 56	CTRP2	5.5861	11.4854	2.2634	10.6305
BICR 6	CTRP2	10.6325	22.6021	0.3702	10.3018

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
253J-BV	CTRP2	2.7545	4.0515	2.7306	15.3358
BFTC-905	CTRP2	3.5478	4.1166	3.5462	9.976
253J	CTRP2	3.6572	4.4387	3.6431	9.2891
CAL-29	CTRP2	3.8832	4.6728	3.8559	7.8289
5637	CTRP2	3.9522	7.3151	2.9069	11.3406
SCaBER	CTRP2	4.2737	4.9473	4.2277	5.2937
RT-4	CTRP2	4.3029	9.5072	2.1684	13.5623
U-BLC1	CTRP2	4.3076	6.3999	3.6852	7.315
647V	CTRP2	4.3379	4.8665	4.3136	4.7897
VM-CUB-1	CTRP2	4.3568	6.3887	3.7388	6.9771
UM-UC-1	CTRP2	4.4422	5.0211	4.3934	4.1817
BC-3C	CTRP2	4.4687	5.0919	4.4026	4.0685
RT-112	CTRP2	4.4754	4.9933	4.4366	3.9255
639V	CTRP2	4.488	4.9463	4.4609	3.8001
TCCSUP	CTRP2	4.5148	4.9861	4.4812	3.6446
HT-1197	CTRP2	4.534	5.0106	4.4962	3.5316
J82	CTRP2	4.5677	5.1292	4.4987	3.4211
JMSU-1	CTRP2	4.5816	5.6259	4.3141	4.0979
UM-UC-3	CTRP2	4.97	6.0343	4.4862	2.4939
HT-1376	CTRP2	4.9968	6.4569	4.2981	3.2301
KU-19-19	CTRP2	5.1009	6.1904	4.5178	2.1067
KMBC-2	CTRP2	5.2042	9.2897	3.0534	9.3186
T24	CTRP2	5.3185	7.1304	4.2201	2.9703
SW1710	CTRP2	5.34	7.29	4.1575	3.195

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HeLa	CTRP2	4.3749	9.4172	2.2777	12.96

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Trifluoperazine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Quetiapine.	Schizophrenia [6A20]	[15]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Mesoridazine.	Schizophrenia [6A20]	[15]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Aripiprazole.	Schizophrenia [6A20]	[16]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Iloperidone.	Schizophrenia [6A20]	[15]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Paliperidone.	Schizophrenia [6A20]	[15]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Perphenazine.	Schizophrenia [6A20]	[16]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Molindone.	Schizophrenia [6A20]	[16]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Thiothixene.	Schizophrenia [6A20]	[16]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Amisulpride.	Schizophrenia [6A20]	[17]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Asenapine.	Schizophrenia [6A20]	[15]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Pimozide.	Schizophrenia [6A20]	[18]

Coadministration of a Drug Treating the Disease Different from Trifluoperazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[19]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Midostaurin.	Acute myeloid leukaemia [2A60]	[15]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Idarubicin.	Acute myeloid leukaemia [2A60]	[15]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Arn-509.	Acute myeloid leukaemia [2A60]	[18]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[20]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Trifluoperazine and Oliceridine.	Acute pain [MG31]	[21]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[22]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[22]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Memantine.	Alzheimer disease [8A20]	[16]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Trifluoperazine when combined with Rivastigmine.	Alzheimer disease [8A20]	[23]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Trifluoperazine when combined with Donepezil.	Alzheimer disease [8A20]	[23]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Trifluoperazine and Metronidazole.	Amoebiasis [1A36]	[24]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[25]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Trimethaphan.	Aneurysm/dissection [BD50]	[26]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Ivabradine.	Angina pectoris [BA40]	[18]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Bepridil.	Angina pectoris [BA40]	[15]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Dronedarone.	Angina pectoris [BA40]	[15]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Amyl nitrite.	Angina pectoris [BA40]	[25]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Nifedipine.	Angina pectoris [BA40]	[25]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[27]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Cilostazol.	Arterial occlusive disease [BD40]	[15]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Posaconazole.	Aspergillosis [1F20]	[15]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Levalbuterol.	Asthma [CA23]	[28]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Terbutaline.	Asthma [CA23]	[29]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Pirbuterol.	Asthma [CA23]	[29]
Ephedrine	DMMV0KW	Moderate	Antagonize the effect of Trifluoperazine when combined with Ephedrine.	Asthma [CA23]	[30]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Salbutamol.	Asthma [CA23]	[28]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Formoterol.	Asthma [CA23]	[29]
Lisdexamfetamine	DM6W8V5	Moderate	Antagonize the effect of Trifluoperazine when combined with Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[30]
Desipramine	DMT2FDC	Moderate	Increased plasma concentrations of Trifluoperazine and Desipramine due to competitive inhibition of the same metabolic pathway.	Attention deficit hyperactivity disorder [6A05]	[31]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[15]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Trifluoperazine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[15]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[15]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Retigabine.	Behcet disease [4A62]	[15]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Cariprazine.	Bipolar disorder [6A60]	[16]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Trifluoperazine and Loperamide.	Bowel habit change [ME05]	[33]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Eribulin.	Breast cancer [2C60-2C6Y]	[15]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Lapatinib.	Breast cancer [2C60-2C6Y]	[15]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Trifluoperazine when combined with Acetylcholine.	Cataract [9B10]	[34]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[35]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[36]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[28]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[36]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[36]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Trifluoperazine and Dihydrocodeine.	Chronic pain [MG30]	[37]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Isoproterenol.	Conduction disorder [BC63]	[28]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Halothane.	Corneal disease [9A76-9A78]	[15]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Sevoflurane.	Corneal disease [9A76-9A78]	[15]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Trifluoperazine and Remifentanil.	Corneal disease [9A76-9A78]	[21]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Probucol.	Coronary atherosclerosis [BA80]	[15]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Clofazimine.	Crohn disease [DD70]	[38]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Mifepristone.	Cushing syndrome [5A70]	[15]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Pasireotide.	Cushing syndrome [5A70]	[15]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Osilodrostat.	Cushing syndrome [5A70]	[18]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Cyclandelate.	Dementia [6D80-6D8Z]	[25]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Sertraline.	Depression [6A70-6A7Z]	[15]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[16]
Selegiline	DM6034S	Moderate	Additive CNS depression effects by the combination of Trifluoperazine and Selegiline.	Depression [6A70-6A7Z]	[39]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Isocarboxazid.	Depression [6A70-6A7Z]	[39]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Escitalopram.	Depression [6A70-6A7Z]	[15]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and OPC-34712.	Depression [6A70-6A7Z]	[16]
Clomipramine	DMINRKW	Moderate	Increased plasma concentrations of Trifluoperazine and Clomipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[31]
Doxepin	DMPI98T	Moderate	Increased plasma concentrations of Trifluoperazine and Doxepin due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[31]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Maprotiline.	Depression [6A70-6A7Z]	[16]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Trifluoperazine and Esketamine.	Depression [6A70-6A7Z]	[24]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Mepenzolate.	Digestive system disease [DE2Z]	[16]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Oxybutynine.	Discovery agent [N.A.]	[16]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Trifluoperazine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[40]
Zonisamide	DM0DTF7	Major	Additive CNS depression effects by the combination of Trifluoperazine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[41]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Trifluoperazine when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[42]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Ethacrynic acid.	Essential hypertension [BA00]	[26]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Nadolol.	Essential hypertension [BA00]	[25]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Solifenacin.	Functional bladder disorder [GC50]	[15]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Tolterodine.	Functional bladder disorder [GC50]	[16]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Trifluoperazine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[43]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Ketoconazole.	Fungal infection [1F29-1F2F]	[15]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[15]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Carvedilol.	Heart failure [BD10-BD1Z]	[25]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[24]
Bumetanide	DMRV7H0	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Bumetanide.	Heart failure [BD10-BD1Z]	[24]
Procarbazine	DMIK367	Moderate	Additive CNS depression effects by the combination of Trifluoperazine and Procarbazine.	Hodgkin lymphoma [2B30]	[39]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[45]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[25]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Trifluoperazine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[24]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Eprosartan.	Hypertension [BA00-BA04]	[25]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Acebutolol.	Hypertension [BA00-BA04]	[25]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Captopril.	Hypertension [BA00-BA04]	[25]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Penbutolol.	Hypertension [BA00-BA04]	[25]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Nebivolol.	Hypertension [BA00-BA04]	[25]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and TAK-491.	Hypertension [BA00-BA04]	[25]
Pindolol	DMD2NV7	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Pindolol.	Hypertension [BA00-BA04]	[25]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Trichlormethiazide.	Hypertension [BA00-BA04]	[25]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Diazoxide.	Hypertension [BA00-BA04]	[25]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Felodipine.	Hypertension [BA00-BA04]	[25]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Quinapril.	Hypertension [BA00-BA04]	[25]
Deserpidine	DMRH7CV	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Deserpidine.	Hypertension [BA00-BA04]	[25]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Telmisartan.	Hypertension [BA00-BA04]	[25]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Irbesartan.	Hypertension [BA00-BA04]	[25]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Hydralazine.	Hypertension [BA00-BA04]	[25]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[24]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[25]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[16]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Amantadine.	Influenza [1E30-1E32]	[46]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and ITI-007.	Insomnia [7A00-7A0Z]	[16]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Trifluoperazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[15]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[15]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Trifluoperazine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[23]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Trifluoperazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[18]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Crizotinib.	Lung cancer [2C25]	[47]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Ceritinib.	Lung cancer [2C25]	[15]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Osimertinib.	Lung cancer [2C25]	[48]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Selpercatinib.	Lung cancer [2C25]	[18]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Lumefantrine.	Malaria [1F40-1F45]	[24]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Halofantrine.	Malaria [1F40-1F45]	[49]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Hydroxychloroquine.	Malaria [1F40-1F45]	[50]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Primaquine.	Malaria [1F40-1F45]	[15]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[51]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Vemurafenib.	Melanoma [2C30]	[15]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and LGX818.	Melanoma [2C30]	[52]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Trifluoperazine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[53]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Trifluoperazine and Lasmiditan.	Migraine [8A80]	[54]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Trifluoperazine and Flibanserin.	Mood disorder [6A60-6E23]	[55]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Panobinostat.	Multiple myeloma [2A83]	[56]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Trifluoperazine and Thalidomide.	Multiple myeloma [2A83]	[57]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Siponimod.	Multiple sclerosis [8A40]	[24]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Fingolimod.	Multiple sclerosis [8A40]	[15]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Ozanimod.	Multiple sclerosis [8A40]	[58]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Romidepsin.	Mycosis fungoides [2B01]	[15]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[15]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[59]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Phenindamine.	Nasopharyngitis [CA00]	[16]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Promethazine.	Nausea/vomiting [MD90]	[16]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Cyclizine.	Nausea/vomiting [MD90]	[16]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Trifluoperazine and Metoclopramide.	Nausea/vomiting [MD90]	[60]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Ondansetron.	Nausea/vomiting [MD90]	[15]
Bupropion	DM5PCS7	Major	Decreased metabolism of Trifluoperazine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[15]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Entrectinib.	Non-small cell lung cancer [2C25]	[24]
Phendimetrazine	DM6TS1N	Moderate	Antagonize the effect of Trifluoperazine when combined with Phendimetrazine.	Obesity [5B80-5B81]	[30]
Amfepramone	DM9YSNQ	Moderate	Antagonize the effect of Trifluoperazine when combined with Amfepramone.	Obesity [5B80-5B81]	[30]
Benzphetamine	DMIJATC	Moderate	Antagonize the effect of Trifluoperazine when combined with Benzphetamine.	Obesity [5B80-5B81]	[30]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Polythiazide.	Oedema [MG29]	[24]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[18]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Lofexidine.	Opioid use disorder [6C43]	[15]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Trifluoperazine and Apraclonidine.	Optic nerve disorder [9C40]	[61]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Rucaparib.	Ovarian cancer [2C73]	[15]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Trifluoperazine and Oxymorphone.	Pain [MG30-MG3Z]	[21]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Trifluoperazine and Dezocine.	Pain [MG30-MG3Z]	[21]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Trifluoperazine and Nalbuphine.	Pain [MG30-MG3Z]	[21]
Methamphetamine	DMPM4SK	Moderate	Antagonize the effect of Trifluoperazine when combined with Methamphetamine.	Pain [MG30-MG3Z]	[62]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Trifluoperazine and Buprenorphine.	Pain [MG30-MG3Z]	[63]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Trifluoperazine and Hydrocodone.	Pain [MG30-MG3Z]	[21]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Triclabendazole.	Parasitic worm infestation [1F90]	[15]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Safinamide.	Parkinsonism [8A00]	[39]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Trifluoperazine when combined with Pergolide.	Parkinsonism [8A00]	[64]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Trifluoperazine when combined with Opicapone.	Parkinsonism [8A00]	[64]
Rasagiline	DM3WKQ4	Moderate	Additive CNS depression effects by the combination of Trifluoperazine and Rasagiline.	Parkinsonism [8A00]	[39]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Trifluoperazine when combined with Levodopa.	Parkinsonism [8A00]	[64]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Pimavanserin.	Parkinsonism [8A00]	[65]
Bromocriptine	DMVE3TK	Moderate	Antagonize the effect of Trifluoperazine when combined with Bromocriptine.	Parkinsonism [8A00]	[64]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Orphenadrine.	Parkinsonism [8A00]	[16]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Methylscopolamine.	Peptic ulcer [DA61]	[16]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Famotidine.	Peptic ulcer [DA61]	[24]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[66]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Lefamulin.	Pneumonia [CA40]	[67]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Degarelix.	Prostate cancer [2C82]	[18]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Trifluoperazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[68]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Enzalutamide.	Prostate cancer [2C82]	[18]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Relugolix.	Prostate cancer [2C82]	[18]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Bicalutamide.	Prostate cancer [2C82]	[18]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Terazosin.	Prostate hyperplasia [GA90]	[25]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Silodosin.	Prostate hyperplasia [GA90]	[25]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[16]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[69]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Trifluoperazine when combined with Neupro.	Restless legs syndrome [7A80]	[64]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[15]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[15]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[15]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Pitolisant.	Somnolence [MG42]	[15]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[15]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Trifluoperazine due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[70]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Lenvatinib.	Thyroid cancer [2D10]	[15]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Trifluoperazine and Papaverine.	Tonus and reflex abnormality [MB47]	[25]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Tacrolimus.	Transplant rejection [NE84]	[15]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[16]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[22]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[16]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Trifluoperazine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[16]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[15]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[15]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Trifluoperazine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[15]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Trifluoperazine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[15]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Trifluoperazine 5 mg tablet	5 mg	Oral Tablet	Oral
Trifluoperazine 10 mg tablet	10 mg	Oral Tablet	Oral
Trifluoperazine 1 mg tablet	1 mg	Oral Tablet	Oral
Trifluoperazine 2 mg tablet	2 mg	Oral Tablet	Oral
Trifluoperazine Hydrochloride 10mg tablet	10mg	Tablet	Oral
Trifluoperazine Hydrochloride 1mg tablet	1mg	Tablet	Oral
Trifluoperazine Hydrochloride 2mg tablet	2mg	Tablet	Oral
Trifluoperazine Hydrochloride 5mg tablet	5mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Trifluoperazine FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [6] Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5.
• [7] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [8] Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 1A2 Enzyme and Relevant Drug Interactions: Review of Articles
• [9] Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact. 2015 Jun 12;14:82.
• [10] Molecular mechanism of trifluoperazine induces apoptosis in human A549 lung adenocarcinoma cell lines. Mol Med Rep. 2009 Sep-Oct;2(5):811-7. doi: 10.3892/mmr_00000177.
• [11] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [12] Rescue of Pink1 Deficiency by Stress-Dependent Activation of Autophagy. Cell Chem Biol. 2017 Apr 20;24(4):471-480.e4. doi: 10.1016/j.chembiol.2017.03.005. Epub 2017 Mar 30.
• [13] Role of TRP channels and NCX in mediating hypoxia-induced [Ca(2+)](i) elevation in PC12 cells. Respir Physiol Neurobiol. 2008 Dec 31;164(3):386-93. doi: 10.1016/j.resp.2008.09.002. Epub 2008 Sep 7.
• [14] Association of high prolactin levels and neuroleptics immediately postpartum. J Neuropsychiatry Clin Neurosci. 1990 Winter;2(1):115. doi: 10.1176/jnp.2.1.115b.
• [15] Canadian Pharmacists Association.
• [16] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [17] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [18] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [19] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [20] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [21] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [22] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [23] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [24] Cerner Multum, Inc. "Australian Product Information.".
• [25] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [26] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [27] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [28] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [29] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [30] Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
• [31] Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
• [32] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [33] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [34] Multum Information Services, Inc. Expert Review Panel.
• [35] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [36] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [37] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [38] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [39] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [40] Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
• [41] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [42] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
• [43] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [44] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [45] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [46] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [47] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [48] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [49] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [50] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [51] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [52] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [53] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [54] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [55] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [56] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [57] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [58] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [59] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [60] Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
• [61] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [62] Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
• [63] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [64] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [65] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [66] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [67] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [68] Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
• [69] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [70] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".